Pneumococcal disease is an important cause of morbidity and mortality in young children, the elderly, and those who are immunocompromised. [1] [2] [3] [4] [5] [6] An effective 7-valent conjugate vaccine has been recommended for prevention of invasive pneumococcal disease in children younger than 2 years of age, and a 23-valent polysaccharide vaccine has been recommended for prevention of invasive pneumococcal disease in the elderly and the chronically ill. [7] [8] [9] [10] While vaccination is preventive against invasive pneumococcal infections, it has not been found effective against nonbacteremic pneumococcal pneumonia in the elderly. [11] [12] [13] Conjugate vaccines have been shown to have some preventive effect against pneumococcal pneumonia in children younger than 2 years old. 14 Unfortunately, vaccine use is far from universal, even in high-risk groups. 15, 16 The problem of undervaccination is complicated by the increasing spread of antibiotic-resistant Streptococcus pneumoniae. 17, 18 As antibiotic resistance complicates treatment of pneumococcal disease, 19 vaccination and other primary prevention strategies, including smoking cessation and treatment of alcoholism and chronic diseases, are becoming more important.
It is important to follow trends in pneumococcal disease mortality so that prevention efforts can be targeted to groups at highest risk of death. While pneumococcal infection is recognized as an important cause of death, few populationbased studies have been conducted to fully assess the burden of pneumococcal disease mortality. We used vital records data to conduct a population-based assessment of pneumococcal disease mortality in the state of California over a 10year period from 1989 through 1998. We examined demographic correlates of pneumococcal disease mortality to identify groups at highest risk. We also assessed temporal trends and seasonality in pneumococcal disease mortality, and examined comorbidities listed as other causes of death to assess the effects of coexisting conditions.
METHODS
We identified deaths due to pneumococcal disease using multiple cause-coded data from vital records for the state of California from 1989 to 1998. California state law requires completion of death certificates, including the assignment of a cause of death or sequence of events leading to death as determined by a physician. Death certificates can specify as many as 20 contributory causes of death. Deaths due to pneumococcal disease were defined as any deaths for which the International Classification of Diseases, 9th revision (ICD-9), code 20 for the underlying cause of death or any of the contributory causes of death indicated pneumococcal pneumonia (ICD-9 code: 481), pneumococcal meningitis (ICD-9 code: 320.1), pneumococcal septicemia (ICD-9 code: 038.2), pneumococcal peritonitis (ICD-9 code: 567.1), or pneumococcal infection of unspecified site (ICD-9 code: 041.2). Deaths due to invasive pneumococcal disease were defined as any deaths due to pneumococcal meningitis, septicemia, peritonitis, or infection of unspecified site. Month of death, demographic information (age, gender, race/ethnicity), and comorbid causes of death were obtained from vital records for all deaths that met the case definition.
Information about the size and demographic breakdown (by age, gender, and race/ethnicity) of California's total population for each year from 1989 to 1998 was obtained from population estimates published by the California Department of Finance. 21 Department of Finance figures are based on census data and estimate annual fluctuations in the population between census years. Department of Finance data divide the California population into five racial/ ethnic categories: white, Hispanic, African American, Asian/ Pacific Islander, and Native American.
Crude pneumococcal disease mortality rates per 100,000 population and 95% confidence intervals (CIs) were calculated for each age group (Ͻ1, 1-4, 5-14, 15-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85ϩ) , gender, and racial/ ethnic group. We used the age distribution of the 2000 U.S. population as a standard to calculate age-adjusted mortality rates and rate ratios by gender and race/ethnicity. 22 Small cells (less than five observations) were collapsed into larger cells in age-adjusted rate and rate ratio calculations to stabilize the variance. We used linear regression analyses and Poisson regression analyses to examine age and temporal trends in pneumococcal disease mortality. When necessary, the scale parameter for Poisson regression models was held fixed to compensate for the effects of underdispersion. We employed the chi-square test to examine seasonal differences in pneumococcal disease-related mortality and to examine differences across age groups. All analyses were conducted using Microsoft Excel 23 and SAS 8.2 software. 24 
RESULTS
Vital records for the State of California recorded 2,235,220 deaths from 1989 to 1998. Pneumococcal disease was reported as a cause of death for 5,265 individuals (2.4 of every 1,000 deaths). Of the 5,265 pneumococcal disease-related deaths found in California's vital records, pneumococcal disease was reported as the underlying cause of death for 3,140 (59.6%) individuals and as a contributory cause of death for 2,125 (40.4%) individuals. Pneumococcal disease was reported as either an underlying or contributory cause of death for more males than females, and nearly three quarters of deaths observed were among the white population ( Table 1 ). The mean age of death due to pneumococcal disease was 69.3 years (medianϭ74, lower quartileϭ55, upper quartileϭ84).
Over the 10-year period examined, the crude mortality rate per year due to pneumococcal disease in California was 1.67 deaths per 100,000 population (95% CI 1.63, 1.72). The age-adjusted pneumococcal disease mortality rate was 2.05 deaths per 100,000 population (95% CI 1.99, 2.10). Age-adjusted mortality rates were higher for males than for females (rate ratio [RR]ϭ1.64; 95% CI 1.55, 1.74). The African American race/ethnicity group had the highest ageadjusted mortality rate due to pneumococcal disease, followed by Native American, white, Hispanic, and Asian/Pacific Islander ( Table 2) .
Pneumococcal disease mortality was higher in infants than in older children and young adults, with a sharp decrease in mortality occurring immediately after the first year of life ( Figure 1 ). Nearly half (47.7%) of all children who died before 15 years of age died during infancy. Of the 62 reported infants who died of pneumococcal disease, 15 (24.2%) died before 2 months of age, 12 (19.4%) died from 2 to 4 months of age, and 16 (25.8%) died from 4 to 6 months of age.
Crude mortality rates for infants were higher in males than in females, but the difference was not as extreme as that observed in the general population (RRϭ1.32; 95% CI 0.80, 2.19) and the sample was small. Mortality among infants was lowest in the Asian/Pacific Islander race/ethnicity group and highest in the African American group, following trends observed in the general population, but mortality among infants differed from general population trends in that considerably higher mortality rates were seen in Hispanic infants than in white infants (Tables 2 and 3) .
Linear regression analyses of the relationship between age and the natural log of mortality rate suggested that mortality rates increase exponentially with age in individuals 15 to 99 years old (ß ϭ.082; 95% CI 0.079, 0.085), with an average increase of 8.5% for each increasing year of age.
For a large majority of pneumococcal disease deaths, pneumococcal pneumonia was listed as an underlying or contributory cause of death (nϭ4,638, 88.09%). Pneumococcal meningitis deaths were less common (nϭ358, 6.80%), followed by deaths from the following: pneumococcal septicemia (nϭ330, 6.27%), pneumococcal disease of unspecified site (nϭ26, 0.49%), and pneumococcal peritonitis (nϭ2, CI ϭ confidence interval 0.04%). Dual sites of pneumococcal infection were reported for 89 individuals (1.69%). Demographic patterns in pneumococcal disease mortality were examined by site of infection for pneumococcal pneumonia, meningitis, and septicemia ( Table 2) . Chi-square tests suggested that deaths due to different types of pneumococcal infection had different age distributions (pϽ0.001). Males had higher age-adjusted rates of pneumococcal mortality than females for both pneumococcal pneumonia (RR ϭ 1.68; 95% CI 1.58, 1.78) and septicemia (RRϭ1.56; 95% CI 1.25, 1.94), but the age-adjusted mortality rate in males was only slightly higher for pneumococcal meningitis (RRϭ1.12; 95% CI 0.90, 1.39).
An examination of reported age and comorbid conditions revealed that 78.9% of all individuals who died of pneumococcal disease (and 57.4% of those who died of invasive pneumococcal disease) belonged to high-risk groups as defined by the Advisory Committee on Immunization Practices (ACIP). 10 Approximately 64.9% of all individuals who died of pneumococcal disease (41.0% of those who died of invasive disease) belonged to high-risk age groups targeted for vaccination (older than 64 years of age). 10 Chronic conditions recognized as indicators for pneumococcal vaccination (cardiomyopathy, chronic heart failure, chronic obstructive pulmonary disease, diabetes mellitus, alcoholism, cerebrospinal fluid leaks, and cirrhosis) were listed as comorbid causes of death for 32.1% of all individuals who died of pneumococcal disease and for 20.1% of those who died of invasive disease. 10 Immunosuppressive conditions that are recognized as indicators for pneumococcal vaccination (HIV, asplenia, Hodgkin's disease, lymphoma, multiple myeloma, leukemia, generalized malignancy, chronic renal failure, nephrotic syndrome, sickle cell disease, and organ transplantation) were listed as comorbid causes of death for 6.6% of all individuals who died of pneumococcal disease and for 12.5% of those who died of invasive disease.
Chi-square tests suggested that the effects of HIV infection on pneumococcal disease mortality differed between age groups (pϽ0.001). While HIV was listed as a comorbid cause of death in 3.2% of all individuals who died of pneumococcal disease, it was listed as a comorbid cause of death in 24.3% of males aged 25-44 who died of pneumococcal disease. Chi-square tests also showed changes over time in the effects of HIV infection on pneumococcal disease mortality (pϭ0.001). The incidence of HIV-associated pneumococcal disease death decreased from 29 reported deaths Poisson regression analyses showed an average decline of 2.8% per year in the crude rate of pneumococcal disease mortality over the 10-year period examined (Figure 2) , ßϭ Ϫ.028; 95% CI -0.037, -0.018. For invasive disease, an average decline in mortality rates of 3.0% per year was observed (ßϭϪ0.031; 95% CI Ϫ0.057, Ϫ0.005). Chi-square analyses showed that the number of pneumococcal disease-related deaths varied (pϽ0.001) by month of the year, reaching its highest in January (meanϭ83.9 deaths; 95% CI 48.6, 119.2) and its lowest in September (meanϭ25.1 deaths; 95% CI 13.0, 17.2).
DISCUSSION
Despite the availability of vaccines that are effective against invasive pneumococcal infections, pneumococcal disease mortality remains significant in the California population. Mortality records do not record the vaccination status of individuals who die of vaccine preventable diseases. Vaccination rates in targeted risk groups, however, were still below 60% in 1999. 15, 16 This falls well below the national objective of 90% vaccination coverage for the year 2010. 9 The ob- served substantial gender and racial/ethnic disparities in pneumococcal disease mortality indicate that special efforts should be made to increase immunization coverage among at-risk individuals in demographic groups with elevated mortality rates, including males and African Americans. The majority of individuals who died of invasive pneumococcal disease fell into at-risk groups targeted for vaccination, suggesting that stricter implementation of recommendations could potentially prevent a large portion of invasive pneumococcal disease deaths. Surveillance data indicate that more than 85% of invasive pneumococcal disease strains found in the United States in individuals older than 65 years old are contained in the polysaccharide vaccine and that more than 80% of strains in children younger than 2 years old are contained in the conjugate vaccine. 1 While vaccines contain the majority of pneumococcal disease strains occurring in the United States, it is important to note that vaccines are not 100% effective and that immunogenicity in the elderly may decrease with age. 13, 25 Public Health Reports / March-April 2005 / Volume 120
The large majority of all pneumococcal disease deaths were from pneumococcal pneumonia infections in the elderly. Evidence to date does not suggest that vaccination has a preventive effect against nonbacteremic pneumococcal pneumonia in the elderly. 11 It was not possible, however, to identify bacteremic vs. nonbacteremic cases of pneumococcal pneumonia based on death certificate reporting. High rates of pneumonia mortality in the elderly caused overall pneumococcal disease mortality rates to increase exponentially with age in adults. Pneumococcal disease mortality rates were more than 30 times higher in adults older than 85 than in infants.
This study examined mortality rates from 1989 to 1998, before pneumococcal vaccination was recommended for infants. 8 Thus, our data provide pneumococcal disease mortality rates in an unvaccinated infant population. Such baseline information may be useful for future research to assess whether infant mortality due to pneumococcal disease declines following ACIP's recommendation that infants be vaccinated. 8 We did not examine vital records for 1999 and 2000 because they were not comparable with earlier records due to the implementation of International Classification of Diseases, 10th revision (ICD-10) coding in 1999. 26 Pneumococcal disease mortality rates were higher among infants than among older children and adolescents. The majority of early childhood deaths due to pneumococcal disease occurred in the first year of life, and even within the first year of life, mortality was highest in early months. A delay of only a few months will result in infants passing unimmunized through the portion of their childhood during which they are at highest risk. Since infant mortality rates were highest in the African American and Hispanic populations, special emphasis should be placed on ensuring the vaccination of infants in these groups. Although similar vaccination coverage levels have been noted for males and females, males had higher age-adjusted rates of pneumococcal disease mortality than females. 15 The higher prevalence of behavioral risk factors, such as alcoholism and smoking, and of diabetes, chronic heart disease, and HIV infection among males may contribute to the observed gender disparity in pneumococcal disease mortality. 10, [27] [28] [29] [30] [31] Even in infancy, however, before any of these risk factors come into play, mortality rates are slightly higher in males than in females. Further research should investigate genetic or other factors that might render males susceptible to pneumococcal infection.
Considerable differences were observed in mortality between different racial/ethnic groups. Nationwide, the African American population has been reported to be substantially undervaccinated in comparison with other racial/ethnic groups. 15, 16 This undervaccination may be partially responsible for elevated invasive pneumococcal disease mortality rates observed in that population. The prevalence of smoking and alcoholism in the African American population has been described as being similar to that in the white population. [29] [30] [31] [32] [33] Observed low rates of pneumococcal disease mortality in Asians/Pacific Islanders may be due in part to lower prevalence of smoking in this group. [29] [30] [31] [32] [33] Vaccination rates in the Asian/Pacific Islander population have been reported to be lower than in the white population, but these estimates were based on small samples and are statistically unstable. 15 Future research should investigate other socioeconomic and health factors that may also be partially responsible for racial/ ethnic differences in pneumococcal disease mortality.
HIV was reported as a comorbid cause of death in nearly one-fourth of pneumococcal disease deaths among 25-to 44-year-old males, the demographic group in which HIV infection is most common. 34 These figures may underestimate the true impact of HIV on pneumococcal disease mortality, as unreported HIV infection may have contributed to additional deaths. Patients with HIV have been targeted by ACIP for vaccination, and although vaccination may not raise antibody levels as efficiently in HIV-infected patients as in immunocompetent individuals, vaccination has been found to be safe and at least partially effective. [35] [36] [37] [38] HIVassociated pneumococcal disease mortality decreased sharply after the introduction of highly active antiretroviral therapy in 1995.
Pneumococcal disease deaths followed a seasonal pattern that peaked in the winter months, roughly reflecting that of influenza. 4 Previous studies have found that influenza-A infection can increase susceptibility to pneumococcal disease. 39 Pneumococcal vaccination programs should attempt to prevent high-risk individuals from continuing through the winter months without receiving pneumococcal vaccine. This problem could be addressed efficiently by combining influenza and pneumococcal disease vaccination campaigns. Previous interventions have documented that offering pneumococcal vaccine in conjunction with influenza vaccine can increase pneumococcal vaccination levels considerably. 40, 41 The observed decrease over time in pneumococcal disease mortality may be related to a reported increase in vaccination, 12 but this relationship is ecologic and should be interpreted with caution. Increased levels of influenza vaccination and the advent of antiretroviral therapy among HIV patients may have also contributed to the observed decrease in pneumococcal disease mortality levels. 15 Population estimates used as denominator data in this study are subject to error. Studies based on death certificate data have a unique set of limitations. [42] [43] [44] Observed mortality rates may be low due to underreporting. In addition, the use of vital records information did not permit us to assess pneumococcal disease morbidity or to examine certain important variables, including the vaccination status and smoking status of individuals who died of pneumococcal disease. The use of death certificates, however, also contributed important strengths to the study, allowing for a population-based approach with high specificity.
